Literature DB >> 21310944

Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification.

Zhe Hou1, Domenick J Falcone, Kotha Subbaramaiah, Andrew J Dannenberg.   

Abstract

Tumor-associated macrophages and high levels of cyclooxygenase-2 (COX-2) are associated with poor prognosis in breast cancer patients, but their potential interdependence has not been evaluated. The objective of this study was to determine whether macrophages regulate COX-2 expression in breast cancer cells. For this purpose, THP-1 cells were cocultured with HCC1954 breast cancer cells. Coculture led to increased COX-2 expression in the HCC1954 cells and elevated prostaglandin E(2) levels in conditioned media. Similar results were observed when THP-1 cells were incubated with HCC1937 breast cancer cells or when human monocyte-derived macrophages were cocultured with HCC1954 cells. Coculture triggered production of reactive oxygen species (ROS) in HCC1954 cells. COX-2 induction was blocked in cells preincubated with an reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor or by silencing p67PHOX, a subunit of NADPH oxidase. ROS production triggered activation of Src and mitogen-activated protein kinases (MAPKs). Blocking Src or MAPK activities or antagonizing the activator protein-1 (AP-1) transcription factor attenuated COX-2 induction in HCC1954 cells. Coculture caused rapid induction of interleukin-1β (IL-1β) in both breast cancer cells and macrophages. Increased IL-1β expression was blocked by an interleukin-1 receptor antagonist (IL-1Ra), suggesting autocrine and paracrine effects. Importantly, macrophage-induced COX-2 expression was blocked in HCC1954 cells preincubated with IL-1Ra or anti-IL-1β IgG. Together, these results indicate that macrophage-mediated induction of COX-2 in breast cancer cells is a consequence of IL-1β-mediated stimulation of ROSSrc→MAPK→AP-1 signaling. IL-1β-dependent induction of COX-2 in breast cancer cells provides a mechanism whereby macrophages contribute to tumor progression and potential therapeutic targets in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310944      PMCID: PMC3086701          DOI: 10.1093/carcin/bgr027

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  56 in total

Review 1.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

3.  Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms.

Authors:  Kotha Subbaramaiah; Philip A Cole; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

4.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.

Authors:  R E Harris; G A Alshafie; H Abou-Issa; K Seibert
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

5.  Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein.

Authors:  Jun-Jie Chen; Wei-Chien Huang; Ching-Chow Chen
Journal:  Mol Biol Cell       Date:  2005-09-29       Impact factor: 4.138

6.  Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

Authors:  Kotha Subbaramaiah; Larry Norton; William Gerald; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

7.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

8.  Nonsteroidal anti-inflammatory drug use and breast cancer risk.

Authors:  M Cotterchio; N Kreiger; M Sloan; A Steingart
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-11       Impact factor: 4.254

9.  Breast cancer and NSAID use: a meta-analysis.

Authors:  S A Khuder; A B Mutgi
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

10.  Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.

Authors:  S Nakatsugi; T Ohta; T Kawamori; M Mutoh; T Tanigawa; K Watanabe; S Sugie; T Sugimura; K Wakabayashi
Journal:  Jpn J Cancer Res       Date:  2000-09
View more
  36 in total

1.  Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages.

Authors:  Delisha A Stewart; Yinmeng Yang; Liza Makowski; Melissa A Troester
Journal:  Mol Cancer Res       Date:  2012-04-24       Impact factor: 5.852

Review 2.  The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer.

Authors:  Britta Weigelt; Cyrus M Ghajar; Mina J Bissell
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

3.  Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.

Authors:  Dipak Panigrahy; Allison Gartung; Jun Yang; Haixia Yang; Molly M Gilligan; Megan L Sulciner; Swati S Bhasin; Diane R Bielenberg; Jaimie Chang; Birgitta A Schmidt; Julia Piwowarski; Anna Fishbein; Dulce Soler-Ferran; Matthew A Sparks; Steven J Staffa; Vidula Sukhatme; Bruce D Hammock; Mark W Kieran; Sui Huang; Manoj Bhasin; Charles N Serhan; Vikas P Sukhatme
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

4.  ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2.

Authors:  Hewang Lee; Hila Roshanravan; Ying Wang; Koji Okamoto; Junghwa Ryu; Shashi Shrivastav; Peng Qu; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-10

5.  Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF-α and the EP4 prostanoid receptor.

Authors:  K M Faisal Khan; Poonam Kothari; Baoheng Du; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2012-01-06       Impact factor: 5.422

6.  A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus.

Authors:  Chong Yuan; William L Smith
Journal:  J Biol Chem       Date:  2014-12-29       Impact factor: 5.157

Review 7.  The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Authors:  Changbin Zhu; Johan M Kros; Caroline Cheng; Dana Mustafa
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

8.  Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.

Authors:  Nune Markosyan; Edward P Chen; Victoire N Ndong; Yubing Yao; Christopher J Sterner; Lewis A Chodosh; John A Lawson; Garret A Fitzgerald; Emer M Smyth
Journal:  Carcinogenesis       Date:  2011-07-18       Impact factor: 4.944

9.  Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB.

Authors:  Hong Li; Matthew L Edin; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Artiom Gruzdev; Jennifer Cheng; Ryan T Dackor; Ping Ming Wang; Carl D Bortner; Stavros Garantziotis; Anton M Jetten; Darryl C Zeldin
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

Review 10.  Aiding and abetting roles of NOX oxidases in cellular transformation.

Authors:  Karen Block; Yves Gorin
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.